Global Biologics and Biosimilars Competitive Landscape Professional Research Report 2025
Research SummaryBiologics are pharmaceutical drugs derived from living organisms, such as proteins, antibodies, or nucleic acids. They are produced using biotechnology processes and are used for the treatment of various diseases, including cancer, autoimmune disorders, and genetic diseases. Biologics are often highly complex and require specialized manufacturing techniques to ensure their safety, efficacy, and consistency. Biosimilars, on the other hand, are biological products that are highly similar to an already approved reference biologic. They are developed to have comparable efficacy, safety, and quality to the reference product and undergo rigorous testing to demonstrate similarity. Biosimilars offer a more affordable alternative to the original biologic, providing increased access to life-saving therapies. They are regulated by health authorities to ensure their quality, efficacy, and safety. Biologics and biosimilars have revolutionized the field of medicine, offering innovative and effective treatment options for patients with various medical conditions.
According to DIResearch's in-depth investigation and research, the global Biologics and Biosimilars market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Biogen, Celltrion, Sobi, 3SBIO, Changchun High Tech, Kanghong Pharma, Innovent Biologics, Gan&Lee, Tonghua Dongbao, United Laboratory etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Biologics and Biosimilars. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Biologics and Biosimilars market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Biologics and Biosimilars market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biologics and Biosimilars industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Biologics and Biosimilars Include:
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Biologics and Biosimilars Product Segment Include:
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Biologics and Biosimilars Product Application Include:
Hospital
Retail Pharmacy
Other
Chapter ScopeChapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Biologics and Biosimilars Industry PESTEL Analysis
Chapter 3: Global Biologics and Biosimilars Industry Porter’s Five Forces Analysis
Chapter 4: Global Biologics and Biosimilars Major Regional Market Size and Forecast Analysis
Chapter 5: Global Biologics and Biosimilars Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Biologics and Biosimilars Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources